Coxevac Evrópusambandið - íslenska - EMA (European Medicines Agency)

coxevac

ceva santé animale - óvirkt coxiella burnetii bóluefni, stofn nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

Valcyte Mixtúruduft, lausn 50 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

valcyte mixtúruduft, lausn 50 mg/ml

cheplapharm arzneimittel gmbh - valganciclovirum hýdróklóríð - mixtúruduft, lausn - 50 mg/ml

Doxycyklin EQL Pharma Tafla 100 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

doxycyklin eql pharma tafla 100 mg

eql pharma ab - doxycyclinum inn - tafla - 100 mg

Caspofungin Accord Evrópusambandið - íslenska - EMA (European Medicines Agency)

caspofungin accord

accord healthcare s.l.u. - caspofungin asetat - candidiasis; aspergillosis - sveppalyf fyrir almenn nota - meðferð innrásar sveppasýkingu í fullorðinn eða börn sjúklingar. meðferð innrásar aspergillosis í fullorðinn eða börn sjúklingum sem svarar til eða þola amfótericín b, fitu blöndum amfótericín b og/eða ítrakónazól. svara ekki meðferð er skilgreint eins og framgangi sýkingu eða bilun til að bæta eftir að minnsta kosti 7 daga áður en lækninga skammta af árangri mikla meðferð. reynslunni meðferð fyrir ráð sveppasýkingu (eins og candida eða aspergillus) í hita, neutropaenic fullorðinn eða börn sjúklingar.

Cancidas (previously Caspofungin MSD) Evrópusambandið - íslenska - EMA (European Medicines Agency)

cancidas (previously caspofungin msd)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - sveppalyf fyrir almenn nota - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Kåvepenin Filmuhúðuð tafla 1 g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

kåvepenin filmuhúðuð tafla 1 g

viatris aps - phenoxymethylpenicillinum kalíum - filmuhúðuð tafla - 1 g

Kåvepenin Filmuhúðuð tafla 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

kåvepenin filmuhúðuð tafla 500 mg

viatris aps - phenoxymethylpenicillinum kalíum - filmuhúðuð tafla - 500 mg

Kåvepenin Filmuhúðuð tafla 800 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

kåvepenin filmuhúðuð tafla 800 mg

viatris aps - phenoxymethylpenicillinum kalíum - filmuhúðuð tafla - 800 mg

Kåvepenin Mixtúrukyrni, dreifa 100 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

kåvepenin mixtúrukyrni, dreifa 100 mg/ml

viatris aps - phenoxymethylpenicillinum kalíum - mixtúrukyrni, dreifa - 100 mg/ml

Kåvepenin Frukt (Kåvepenin (mixt. 50 mg/ml)) Mixtúrukyrni, dreifa 50 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

kåvepenin frukt (kåvepenin (mixt. 50 mg/ml)) mixtúrukyrni, dreifa 50 mg/ml

viatris aps - phenoxymethylpenicillinum kalíum - mixtúrukyrni, dreifa - 50 mg/ml